Bremelanotide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-26. Numbers and descriptions here follow the published literature rather than marketing material.
Bremelanotide acts as a non-selective agonist at melanocortin receptors, with reported activity at MC1R, MC3R, MC4R and MC5R. The proposed basis for its central effects is activation of MC4R populations in the hypothalamus, a region associated with appetite and reproductive signalling. Because the peptide carries a net positive charge and polar side chains, it does not cross biological membranes freely, which is one reason oral administration is not the standard route. Effects generally appear within an hour of parenteral administration and are described as centrally mediated rather than peripheral.
Bremelanotide, developed under the code PT-141, is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone. Its structure is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH, with a lactam bridge joining the aspartate and lysine side chains. The molecule has the formula C50H68N14O10 and a monoisotopic mass near 1025 daltons. It is commonly prepared as the acetate salt and appears as a white to off-white lyophilised powder in solid form. The free acid is the pharmacologically relevant species, while the counter-ion improves handling and dissolution.
Early research on PT-141 grew out of work on melanotan II, a related cyclic peptide studied for pigmentation. Investigators observed that centrally acting melanocortin agonists also influenced sexual behaviour in animal models, and the programme shifted toward that endpoint. A nasal formulation was evaluated in clinical trials but showed inconsistent absorption, and later studies used subcutaneous administration instead. Regulatory approval in the United States followed in 2019 for a defined population of premenopausal women with acquired, generalised hypoactive sexual desire disorder. That approval was specific to that group rather than a broad indication.
Identity and purity are established with orthogonal methods rather than a single test. Reverse-phase high-performance liquid chromatography with ultraviolet detection gives a purity figure by area normalization, while mass spectrometry confirms the expected molecular ion. Amino acid analysis or peptide mapping can detect sequence errors that a mass value alone would miss, and residual counterion content is sometimes measured separately. Common impurities include truncated sequences, oxidized residues, and deamidated products; reporting them individually is more informative than a single composite purity number.
Lyophilized peptide arrives as a white to off-white cake or powder and is normally held at minus twenty degrees Celsius or colder for extended periods. Short-term bench work at ambient temperature is tolerable for minutes, not hours, because the solid is hygroscopic and picks up moisture that promotes hydrolysis. Vials should stay in a desiccator or a sealed bag with desiccant, protected from light, since aromatic residues in the sequence are susceptible to photo-oxidation. Inventory records that note arrival date and storage location reduce the chance of using degraded material.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Cyclic heptapeptide | Synthetic analogue of alpha-MSH |
| Molecular formula | C50H68N14O10 | Acetate salt form commonly reported |
| Molecular mass | ~1025 Da | Monoisotopic value near 1025.2 |
| Key structural motif | Lactam bridge | Asp side chain to Lys side chain |
| Solid appearance | White to off-white powder | Lyophilised and hygroscopic |
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Bremelanotide is a moderately large peptide with a molecular mass near 1025 daltons. In lyophilised form it appears as a white to off-white powder and is freely soluble in water and other polar solvents. The intact lactam ring is essential for receptor affinity, while linearised fragments bind far more weakly. Solutions are sensitive to extremes of pH and to prolonged exposure to light and heat, so handling typically involves buffered conditions and cold storage. Its short plasma half-life reflects rapid distribution and clearance rather than chemical breakdown inside the vial.
Development of the peptide passed through several delivery formats, including an intranasal version tested in early trials and an injectable version that entered later clinical study. Regulatory approval for a subcutaneous product in the United States was granted in 2019 after review of controlled trials in premenopausal women. Outside the clinic, the compound circulates in research and non-pharmaceutical markets under its code name, where identity and purity vary considerably between suppliers. Synonyms appearing across technical literature include bremelanotide, PT-141, and Palatin 141.
PT-141 is the research designation for bremelanotide, a synthetic cyclic heptapeptide developed as a melanocortin receptor agonist. The peptide contains seven amino acids with an internal lactam bridge that constrains the backbone into a stable ring. Cyclisation of this kind improves resistance to enzymatic degradation relative to linear analogues. The compound was first explored for effects on melanin production, because several melanocortin receptors influence pigmentation. Its later association with sexual desire emerged from observations made during that early work, and the molecule became the subject of a separate development programme.
== Diagnosis == AGAT deficiency can be suspected from clinical findings, although there is significant phenotypic overlap with the most common presenting symptoms of intellectual disability and muscle weakness. Laboratory testing of plasma and urine will show decreased levels of creatine and guanidinoacetate. Non-specific elevations of metabolites on urine testing that are normalized to creatinine may appear falsely elevated. Magnetic resonance spectroscopy (MRS) of the brain will also show an absence of creatine, which is normally present. This finding is not specific to AGAT deficiency, it can be observed in all three cerebral creatine deficiencies. The combination of biochemical testing and MRS findings can be strongly suggestive of AGAT deficiency. Confirmation would most often be done with molecular testing of GATM. Identification of biallelic pathogenic variants in GATM would be confirmation of a diagnosis of AGAT deficiency. Uncertain findings on molecular testing may be able to be confirmed by enzyme assays, or by measuring creatine uptake in fibroblasts. Prenatal testing for AGAT deficiency can be performed on chorionic villi samples if the causative pathogenic variants in the family are known.
Addition of molecular oxygen to ribulose-1,5-bisphosphate produces 3-phosphoglycerate (PGA) and 2-phosphoglycolate (2PG, or PG). PGA is the normal product of carboxylation, and productively enters the Calvin cycle. Phosphoglycolate, however, inhibits certain enzymes involved in photosynthetic carbon fixation (hence is often said to be an 'inhibitor of photosynthesis'). It is also relatively difficult to recycle: in higher plants it is salvaged by a series of reactions in the peroxisome, mitochondria, and again in the peroxisome where it is converted into glycerate. Glycerate reenters the chloroplast and by the same transporter that exports glycolate. A cost of 1 ATP is associated with conversion to 3-phosphoglycerate (PGA) (Phosphorylation), within the chloroplast, which is then free to re-enter the Calvin cycle. Several costs are associated with this metabolic pathway; the production of hydrogen peroxide in the peroxisome (associated with the conversion of glycolate to glyoxylate). Hydrogen peroxide is a dangerously strong oxidant which must be immediately split into water and oxygen by the enzyme catalase. The conversion of 2× 2Carbon glycine to 1× C3 serine in the mitochondria by the enzyme glycine-decarboxylase is a key step, which releases CO2, NH3, and reduces NAD to NADH. Thus, one CO2 molecule is produced for every two molecules of O2 (two deriving from RuBisCO and one from peroxisomal oxidations). The assimilation of NH3 occurs via the GS-GOGAT cycle, at a cost of one ATP and one NADPH.
Human fat was mentioned in European pharmacopoeias since the 16th century as an important fatty component of quality deemed ointments and other pharmaceuticals in Europe. In old recipes human adipose tissue was mentioned as Pinguedo hominis, or Axungia hominis. The German medicinal Johann Agricola (1496–1570) described the recovery of human fat and its applications. In traditional medicine in Europe, human fat was believed to have a healing magic significance until the 19th century. Many executioners recovered the fat from the bodies of their executants, called "Armsünderfett" or "Armsünderschmalz" (German: fat or grease from poor sinners put to death), and sold it. For some executioners the marketing of human fat was a major source of revenue. The human fat was used to make ointments for treatment of various diseases such as bone pain, toothache and gout. It was also regarded as a panacea for particular diseases associated with cachexia (e.g. tuberculosis). Also an analgesic effect in rheumatoid arthritis was attributed to human fat. From the late 19th century, human fat was produced and offered under the trade name Humanol as a sterile, liquified preparation for injections in Germany. In 1909 it was introduced for surgical treatment of scars, wound disinfection, and wound revisions. In the 1920s it became out of fashion after low cure rates and the incidence of fat embolisms caused by its application.
== Education == High received an A.B. in chemistry at Harvard University in 1972. She started her medical training at the University of North Carolina (UNC) School of Medicine, during which she took a leave of absence to work in a chemistry research lab at UNC. After returning and completing her medical degree in 1978, High continued with a residency in internal medicine. She then became a hematology fellow at Yale University under the supervision of Edward J Benz Jr, during which she worked on the molecular genetics of globin genes and oncogenes.
=== 1971–1972: Islands === After a search for a drummer to replace McCulloch, Ian Wallace was secured. Fripp was re-energised by the addition of a new member, and he joined Collins and Wallace to audition singers and bassists. Singers who tried out included Bryan Ferry of Roxy Music (Sinfield would produce Roxy Music's first album in 1972) and even one of the band's managers, John Gaydon. The position eventually went to Raymond "Boz" Burrell. John Wetton was invited to join on bass, but declined in order to join Family instead. Rick Kemp (later of Steeleye Span) rehearsed with the band, but declined the final offer to formally join. Fripp decided to teach Burrell to play bass rather than continue the labored auditions. Though he had not played bass before, Burrell had played enough acoustic guitar to assist him in learning the instrument quickly. Wallace was able to further instruct Burrell in functioning on the instrument in a rhythm section.With a line-up now complete, King Crimson began touring in May 1971, the first time they had played live since the original line-up's last show on 14 December 1969. The concerts were well received, but musical differences and the somewhat wilder lifestyles of Collins, Wallace, and Burrell alienated the non-drug-taking Fripp, who began to withdraw socially from his bandmates, creating further tension. In 1971, the new King Crimson formation recorded Islands.
Sources: en.wikipedia.org
1993/3173) Education (Individual Pupils' Achievements) (Information) Regulations 1993 (S.I. 1993/3182) Education (European Economic Area) (Amendment) Regulations 1993 (S.I. 1993/3183) Education (European Economic Area) (Scotland) Regulations 1993 (S.I. 1993/3184) Liquor Licensing (Fees) (Scotland) Order 1993 (S.I. 1993/3185) Advice and Assistance (Assistance by Way of Representation) (Scotland) Amendment (No. 2) Regulations 1993 (S.I. 1993/3186) Advice and Assistance (Financial Limit) (Scotland) Regulations 1993 (S.I. 1993/3187) Education (Grant–maintained Schools) (Initial Sponsor Governors) Regulations 1993 (S.I. 1993/3188) Education (Acquisition of Grant-maintained Status) (Ballot Information) Regulations 1993 (S.I. 1993/3189) Supreme Court Fees (Amendment) Order 1993 (S.I. 1993/3191) Cod and Saithe (Specified Sea Areas) (Prohibition of Fishing) Order 1993 (S.I. 1993/3192) Haddock, Hake, Nephrops, Plaice and Sole (Specified Sea Areas) (Prohibition of Fishing) Order 1993 (S.I. 1993/3193) Social Security (Severe Disablement Allowance) Amendment Regulations 1993 (S.I. 1993/3194) Doncaster Borough Council (North Bridge Relief Road) (Crossing of Navigable Waterway (Sheffield and South Yorkshire Navigation River Don New Cut)) Scheme 1991 Confirmation Instrument 1993 (S.I. 1993/3195) Education (Distribution by Schools of Information about Further Education Institutions) (England) Regulations 1993 (S.I. 1993/3197) Nitrate Sensitive Areas (Designation) (Amendment) Order 1993 (S.I. 1993/3198) Broadcasting (Restrictions on the Holding of Licences) (Amendment) Order 1993 (S.I.
Edward Calvin Kendall (March 8, 1886 – May 4, 1972) was an American biochemist. In 1950, Kendall was awarded the Nobel Prize for Physiology or Medicine along with Swiss chemist Tadeusz Reichstein and Mayo Clinic physician Philip S. Hench, for their work with the hormones of the adrenal glands. Kendall not only researched the adrenal glands, he also isolated thyroxine, a hormone of the thyroid gland and worked with the team that crystallized glutathione and identified its chemical structure. Kendall was a biochemist at the Graduate School of the Mayo Foundation at the time of the Nobel award. He received his education at Columbia University. After retiring from his job with the Mayo Foundation, Kendall joined the faculty at Princeton University, where he remained until his death in 1972. Kendall Elementary School, in Norwalk is named for him.
=== RNA and DNA have distinct chemical properties === When first studied in the early 1900s, the chemical and biological differences between RNA and DNA were not apparent, and they were named after the materials from which they were isolated; RNA was initially known as "yeast nucleic acid" and DNA was "thymus nucleic acid". Using diagnostic chemical tests, carbohydrate chemists showed that the two nucleic acids contained different sugars, whereupon the common name for RNA became "ribose nucleic acid". Other early biochemical studies showed that RNA was readily broken down at high pH, while DNA was stable (although denatured) in alkali. Nucleoside composition analysis showed first that RNA contained similar nucleobases to DNA, with uracil instead of thymine, and that RNA contained a number of minor nucleobase components, e.g. small amounts of pseudouridine and dimethylguanine.
The Appalachian belt includes the plateaus sloping southward to the Atlantic Ocean in New England, and southeastward to the border of the coastal plain through the central and southern Atlantic states; and on the northwest, the Allegheny and Cumberland plateaus declining toward the Great Lakes and the interior plains. A remarkable feature of the belt is the longitudinal chain of broad valleys, including the Great Appalachian Valley, which in the southerly sections divides the mountain system into two unequal portions, but in the northernmost lies west of all the ranges possessing typical Appalachian features, and separates them from the Adirondack group. The mountain system has no axis of dominating altitudes, but in every portion, the summits rise to rather uniform heights, and, especially in the central section, the various ridges and intermontane valleys have the same trend as the system itself. None of the summits reaches the region of perpetual snow. In Pennsylvania, there are over sixty summits that rise over 2,500 ft (800 m); the summits of Mount Davis and Blue Knob rise over 3,000 ft (900 m). In Maryland, Eagle Rock and Dans Mountain are conspicuous points reaching 3,162 and 2,882 ft (964 and 878 m) respectively. On the same side of the Great Valley, south of the Potomac, are the Pinnacle 3,007 feet (917 m) and Pigeon Roost 3,400 ft (1,000 m). In West Virginia, more than 150 peaks rise above 4,000 ft (1,200 m), including Spruce Knob 4,863 ft (1,482 m), the highest point in the Allegheny Mountains. A number of other points in the state rise above 4,800 ft (1,500 m).
== Toxicity and safety == Glycerol has very low toxicity when ingested; its LD50 oral dose for rats is 12600 mg/kg and 8700 mg/kg for mice. It does not appear to cause toxicity when inhaled, although changes in cell maturity occurred in small sections of lung in animals under the highest dose measured. A sub-chronic 90-day nose-only inhalation study in Sprague Dawley rats exposed to 0.03, 0.16 and 0.66 mg of glycerin per liter of air for 6-hour continuous sessions revealed no treatment-related toxicity other than minimal metaplasia of the epithelium lining at the base of the epiglottis in rats exposed to 0.66 mg/L glycerin.
Sources: en.wikipedia.org
== Pharmacology == Computer models suggest fentanyl binds to μ-opioid receptors in its protonated form. Fluorination of fentanyl at the 3-position lowers the pKa of its conjugate acid from 8.4 to 6.8, a change designed to reduce its systemic effects while maintaining its potency in inflamed tissue, as this is a more acidic environment (pH 5–7) than non-inflamed tissue (pH 7.4). In experiments on rats with different types of inflammatory pain, it has been shown that NFEPP produces injury-restricted analgesia, while exhibiting reduced typical opiate effects such as respiratory depression, sedation, constipation, and chemical seeking behavior. As a result, NFEPP has the potential to reduce opioid addiction and dependency, as there is no effect on users who are not actually suffering from pain, as the chemical does not interact with non-inflamed brain tissue until much higher doses are reached. Further research indicates other fluorinated derivatives of fentanyl, such as β-fluorofentanyl (FF3) or 2'-fluoro β-fluorofentanyl (RR-49), may be more effective in achieving high potency in damaged tissue with low potency in undamaged tissue.
== Ionic kosmotropes == Ionic kosmotropes tend to be small or have high charge density. Some ionic kosmotropes are CO2−3, SO2−4, HPO2−4, Mg2+, Li+, Zn2+ and Al3+. Large ions or ions with low charge density (such as Br−, I−, K+, Cs+) instead act as chaotropes. Kosmotropic anions are more polarizable and hydrate more strongly than kosmotropic cations of the same charge density. A scale can be established if one refers to the Hofmeister series or looks up the free energy of hydrogen bonding (
In 1990, Haire and Gibson estimated mendelevium metal to have an enthalpy of sublimation between 134 and 142 kJ/mol. Divalent mendelevium metal should have a metallic radius of around 194±10 pm. Like the other divalent late actinides (except the once again trivalent lawrencium), metallic mendelevium should assume a face-centered cubic crystal structure. Mendelevium's melting point has been estimated at 800 °C, the same value as that predicted for the neighbouring element nobelium. Its density is predicted to be around 10.3±0.7 g/cm3.
cyclin family proteins: Cyclin D, Cyclin E transcriptional regulators: Myc, E2f1, p130 cyclin-dependent kinase inhibitors (CKIs): p27Kip1, p21, Wee1 centriole proteins: Cep250, Ninein There are approximately seventy human FBPs, several of which are involved in cell cycle control as a component of SCF complexes. Skp2 is an FBP that binds CKIs such as p27Kip1 and p21. Skp2 binds p27Kip1 only when two conditions are met: p27Kip1 is phosphorylated by E/A/CKD2 and bound to Cks1. As a consequence of binding Skp2, p27Kip1 is ubiquitinated and targeted for degradation in late G1 and early S. SCF-Skp2 also targets p130 for degradation in a phosphorylation dependent manner. Beta-transducin repeat-containing protein (βTRCP) is an FBP that targets emi1—an APC/C-Cdh1 inhibitor—and wee1 for degradation during early mitosis. βTRCP recognizes these substrates after they are phosphorylated by Polo-like kinase 1 or Cyclin B-CDK1. Fbw7, which is the human homolog of cdc4 in yeast, is an FBP that targets Cyclin E, Myc, Notch and c-Jun for degradation. Fbw7 is stable throughout the cell cycle and is localized to the nucleus due to the presence of a nuclear localization sequence (NLS). SCF-Fbw7 targets Sic1—when at least six out of nine possible sites are phosphorylated—and Swi5 for degradation. Since Sic1 normally prevents premature entry into S-phase by inhibiting Cyclin B-CDK1, targeting Sic1 for degradation promotes S-phase entry.
Sources: en.wikipedia.org
PT-141 was the development code used for bremelanotide during its preclinical and early clinical programme. The peptide is now generally referred to by its international nonproprietary name.
The two compounds share the same cyclic core and are both non-selective melanocortin agonists. They differ chiefly at the C-terminus, where bremelanotide carries a free carboxylic acid and melanotan II a terminal amide.
Receptor binding profiles are well characterised in vitro, but the downstream pathway linking MC4R activation to behavioural effects is not fully mapped. Several intermediate neural circuits have been proposed without definitive confirmation.
Cold storage at minus twenty degrees Celsius or below is typical, with desiccant and protection from light. The solid form is far more stable than any solution.